SBIR Phase I: Catheters with Anticoagulation and Fibrinolytic Properties

SBIR 第一期：具有抗凝和纤溶特性的导管

• 批准号: 0319525
• 负责人: Ying Jun Du
• 金额: $ 10万
• 依托单位: Spire Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0319525&HistoricalAwards=false
• 关键词: SBIR; Phase; Catheters; Anticoagulation; Fibrinolytic

This Small Business Innovation Research (SBIR) Phase I project will explore an antithrombotic coating on catheters through a newly developed surface treatment technique, electron cyclotron resonance (ECR). Such catheters would display improved device functionality by extending the period between catheter replacements and decreasing morbidity and mortality. ECR plasma can be spatially localized to treat the lumen and external surfaces separately and uniformly. Albumin and tissue plasminogen activator (tPA) can be coated onto polymeric surfaces successfully. In the proposed project, a new approach, enhancing both anticoagulation through albumin (Alb)-heparin (H) complex and fibrinolysis through tPA concurrently, will be investigated. The commercial application of this project will be in the area of medical products that contact blood, e.g., catheters. The project could lead to a low-cost commercial surface modification method for end stage renal disease (ESRD) catheters. Catheters that possess mechanisms to fight thrombosis complications would greatly extend the period between catheter replacements and therefore benefit patients.

该小型企业创新研究（SBIR）第一阶段项目将通过新开发的表面处理技术，电子回旋共振（ECR），探索导管上的抗血栓涂层。 这种导管将通过延长导管更换之间的时间并降低发病率和死亡率来显示改进的装置功能。 ECR等离子体可以在空间上局部化，以单独且均匀地处理内腔和外表面。 白蛋白和组织型纤溶酶原激活剂（tPA）可以成功地涂覆到聚合物表面上。 在拟议的项目中，将研究一种新的方法，通过白蛋白（Alb）-肝素（H）复合物同时增强抗凝作用和通过tPA增强纤溶作用。 该项目的商业应用将在与血液接触的医疗产品领域，例如，导尿管 该项目可能导致终末期肾病（ESRD）导管的低成本商业表面改性方法。 具有抗血栓形成并发症机制的导管将大大延长导管更换之间的时间，从而使患者受益。